Assertio Holdings Inc ASRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ASRT is a good fit for your portfolio.
News
-
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
-
Sig Kirk Joins Assertio Board of Directors
-
Assertio to Present at LD Micro Invitational Conference in New York City
-
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Thinking about buying stock in Marathon Digital, Assertio, Ocean Biomedical, Terns Pharmaceuticals, or NextCure?
-
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
-
March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT
-
DEADLINE ALERT for ASRT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Trading Information
- Previous Close Price
- $0.85
- Day Range
- $0.84–0.88
- 52-Week Range
- $0.74–8.01
- Bid/Ask
- $0.86 / $0.88
- Market Cap
- $83.52 Mil
- Volume/Avg
- 111,969 / 966,862
Key Statistics
- Price/Earnings (Normalized)
- 1.41
- Price/Sales
- 0.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 9.79%
Company Profile
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 30
- Website
- https://www.assertiotx.com
Comparables
Valuation
|
Metric
|
ASRT
|
COLL
|
SUPN
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.41 | 6.83 | 113.81 |
Price/Book Value | 0.58 | 5.99 | 1.82 |
Price/Sales | 0.40 | 2.71 | 2.80 |
Price/Cash Flow | 1.22 | 6.06 | 14.13 |
Price/Earnings
ASRT
COLL
SUPN
Financial Strength
|
Metric
|
ASRT
|
COLL
|
SUPN
|
|---|---|---|---|
Quick Ratio | 1.30 | 1.07 | 1.38 |
Current Ratio | 1.83 | 1.17 | 1.70 |
Interest Coverage | −85.86 | 1.72 | −2.18 |
Quick Ratio
ASRT
COLL
SUPN
Profitability
|
Metric
|
ASRT
|
COLL
|
SUPN
|
|---|---|---|---|
Return on Assets (Normalized) | −87.36% | 18.85% | 2.53% |
Return on Equity (Normalized) | −156.35% | 117.55% | 4.09% |
Return on Invested Capital (Normalized) | −128.46% | 28.83% | 2.73% |
Return on Assets
ASRT
COLL
SUPN
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Gtcsxqzd | Hpzz | $73.0 Bil | |
MKKGY
| Merck KGaA ADR | Qynqlczvht | Fzwpm | $69.8 Bil | |
HLN
| Haleon PLC ADR | Lsgzqvs | Zlv | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Bxclmhnvz | Xwrq | $14.6 Bil | |
VTRS
| Viatris Inc | Dnzkjtmtf | Bpxb | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zltfbknt | Kff | $12.6 Bil | |
CTLT
| Catalent Inc | Yjckxhvn | Mgvfm | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Wdjtjkvdm | Mwk | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Vdgwwnkt | Sdjy | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Gscnyssdh | Bnwzfc | $3.6 Bil |